# US 2017/0281833 A1 · Multi-layer biodegradable device having adjustable drug release profile

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281833 A1
- Document ID: US20170281833A1
- Status: Published application
- Kind: A1
- Application number: 15/624,304
- Filed: 2017-06-15
- Published: 2017-10-05
- Earliest claimed: 2013-03-11
- Assignees: BioInspire Technologies, Inc.
- Applicants: BioInspire Technologies, Inc.
- Inventors: Dorna HAKIMIMEHR; Kyle HAMMERICK
- Web page: https://patentgrep.com/patent/US20170281833A1

## CPC

- A61L 31/046: {Fibrin; Fibrinogen}
- A61B 17/24: for use in the oral cavity, larynx, bronchial passages or nose (for medical inspection of cavities or tubes in the body A61B1/00); Tongue scrapers
- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/0043: {Nose}
- A61K 31/56: Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61L 31/028: {Other inorganic materials not covered by A61L31/022 - A61L31/026}
- A61L 31/047: {Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046}
- A61L 31/06: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds {(A61L31/041 takes precedence)}
- A61L 31/08: Materials for coatings
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61M 31/002: {Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time (artificial gland structures or devices A61F2/022; intra-uterine contraceptive devices A61F6/14; tampons for introducing into the vagina A61F13/20, A61L15/00; suppositories or bougies for intra-vaginal or intra-uterine application A61K9/02; physical forms of medicinal preparations for sustained or differential drug release A61K9/20, A61K9/50)}
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/02: for peripheral neuropathies
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 41/00: Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61L 2300/41: Anti-inflammatory agents, e.g. NSAIDs
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/606: Coatings
- A61L 2300/608: having two or more layers
- A61L 2300/61: containing two or more active agents in different layers
- A61L 2420/08: Coatings comprising two or more layers
- Y10T 156/10: Methods of surface bonding and/or assembly therefor
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

Methods and apparatus for a biodegradable multi-layer device suitable for medical applications are provided, wherein the device is formed from multiple film-layers configured to have different characteristics from one another such as different release profiles for therapeutic agents, adhesive properties, stiffness properties, and solubility properties. The film-layers may include a solid fibrinogen component. A device having multiple film-layers may take a non-adherent form during delivery to a target location within or on tissue, and thereafter may be exposed to moisture to take an adherent form on the tissue. The device may include a number of additives, including materials to improve the mechanical properties of the device, or one or more therapeutic or contrast agents.

## Claims

### Claim 1

A method for applying a device in a sinus of a patient, the method comprising:
advancing the device comprising a first film-layer and a second film-layer to the sinus, the first film-layer comprising fibrinogen and a first therapeutic agent, the second film-layer comprising fibrinogen and a second therapeutic agent;
applying the device on sinus tissue in the sinus;
releasing the first therapeutic agent into the sinus tissue from the first film-layer at a first release profile; and
releasing the second therapeutic agent into the sinus tissue from the second film-layer at a second release profile different from the first release profile.

### Claim 2 (depends on 1)

The method of claim 1, wherein applying the device to the sinus tissue comprises applying the device to the sinus tissue after sinus surgery.

### Claim 3 (depends on 1)

The method of claim 1, wherein applying the device to the sinus tissue comprises applying the device to the sinus tissue of the patient suffering from sinusitis.

### Claim 4 (depends on 1)

The method of claim 1, wherein the first film-layer is formed by processing a first composition comprising the fibrinogen, the first therapeutic agent, and a first amount of non-aqueous solvent and the second film-layer is formed by processing a second composition comprising the fibrinogen, the second therapeutic agent, and a second amount of non-aqueous solvent different from the first amount of non-aqueous solvent.

### Claim 5 (depends on 1)

The method of claim 1, wherein the first and second film-layers further comprise calcium salt.

### Claim 6 (depends on 5)

The method of claim 5, wherein the calcium salt comprises calcium chloride.

### Claim 7 (depends on 1)

The method of claim 1, wherein the first and second film-layers further comprise polyethylene glycol.

### Claim 8 (depends on 1)

The method of claim 1, wherein the first film-layer has a first amount of therapeutic agent and the second film-layer has a second amount of the second therapeutic agent different from the first amount.

### Claim 9 (depends on 1)

The method of claim 1, wherein the first film-layer and the second film-layer are bonded using an intermediate layer disposed between the first film-layer and the second film-layer.

### Claim 10 (depends on 9)

The method of claim 9, wherein the intermediate layer is configured to dissolve to create a reservoir, pores, void, or channel between the first film-layer and the second film-layer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the first therapeutic agent or the second therapeutic agent or both comprise one or more anti-inflammatory agents, anti-allergenic agents, anti-bacterial agents, anti-viral agents, anticholinergic agents, antihistamines, antithrombotic agents, anti-scarring agents, antiproliferative agents, antihypertensive agents, anti-restenosis agents, healing promoting agents, vitamins, proteins, genes, growth factors, cells, RNA, or DNA.

### Claim 12 (depends on 1)

The method of claim 1, wherein the first therapeutic agent or the second therapeutic agent or both comprise a steroidal anti-inflammatory agent.

### Claim 13 (depends on 1)

The method of claim 1, wherein the first therapeutic agent or the second therapeutic agent or both are fluticasone propionate.

### Claim 14 (depends on 1)

The method of claim 1, wherein the first therapeutic agent and the second therapeutic agent are the same type of therapeutic agent.

### Claim 15 (depends on 1)

The method of claim 1, wherein the device is configured to form a fibrin patch upon exposure to moisture in the sinus.

### Claim 16 (depends on 1)

The method of claim 1, wherein the first film-layer or the second film-layer or both further comprise thrombin mixed with the fibrinogen.

### Claim 17 (depends on 1)

The method of claim 1, wherein the first film-layer or the second film-layer or both are coated with a protective layer.

### Claim 18 (depends on 1)

The method of claim 1, wherein the first film-layer and the second film-layer are configured to biodegrade within the sinus.

### Claim 19 (depends on 1)

The method of claim 1, wherein advancing the device comprises advancing the device using a delivery device, and wherein applying the device to the sinus tissue comprises deploying the device from the delivery device.

### Claim 20 (depends on 1)

The method of claim 1, wherein applying the device to the sinus tissue comprises applying the device to the sinus tissue to promote healing of iatrogenic wounds and reduce formation of post-operative lesions.
